Q-omics provides the consensus-scored RBMY1F profile across patient tissues and cancer cell-line models. RBMY1F expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RBMY1F is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, RBMY1F RNA expression shows 517 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight LUSC, KIRC, and BLCA as cancer lineages where RBMY1F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMY1F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMY1F survival associations across molecular data types. RBMY1F RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMY1F RNA expression–survival associations across cancer types. High RBMY1F expression shows unfavorable associations in LUSC, LAML, THYM, LIHC and LUAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify LUSC as the clearest survival context for RBMY1F RNA expression.
This table summarizes RBMY1F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMY1F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMY1F shows lower tumor expression in KIRC. The KIRC box plot shows higher RBMY1F RNA expression in normal versus tumor tissue (log2 FC = −0.002, t-test p = .043).
This table shows molecular features associated with RBMY1F in patient tissues and cancer cell lines. In patient samples, RBMY1F shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RBMY1F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
